BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 20925951)

  • 1. Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: the CINDERELLA trial.
    Combs SE; Burkholder I; Edler L; Rieken S; Habermehl D; Jäkel O; Haberer T; Haselmann R; Unterberg A; Wick W; Debus J
    BMC Cancer; 2010 Oct; 10():533. PubMed ID: 20925951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial.
    Combs SE; Kieser M; Habermehl D; Weitz J; Jäger D; Fossati P; Orrechia R; Engenhart-Cabillic R; Pötter R; Dosanjh M; Jäkel O; Büchler MW; Debus J
    BMC Cancer; 2012 Apr; 12():137. PubMed ID: 22472035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.
    Combs SE; Kieser M; Rieken S; Habermehl D; Jäkel O; Haberer T; Nikoghosyan A; Haselmann R; Unterberg A; Wick W; Debus J
    BMC Cancer; 2010 Sep; 10():478. PubMed ID: 20819220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: the MARCIE trial.
    Combs SE; Edler L; Burkholder I; Rieken S; Habermehl D; Jäkel O; Haberer T; Unterberg A; Wick W; Debus J; Haselmann R
    BMC Cancer; 2010 Nov; 10():615. PubMed ID: 21062428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial.
    Combs SE; Habermehl D; Ganten T; Schmidt J; Edler L; Burkholder I; Jäkel O; Haberer T; Debus J
    BMC Cancer; 2011 Feb; 11():67. PubMed ID: 21314962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II Trial Evaluating Carbon Ion Radiotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma.
    Kong L; Hu J; Guan X; Gao J; Lu R; Lu JJ
    J Cancer; 2016; 7(7):774-83. PubMed ID: 27162535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiochemotherapy with temozolomide as re-irradiation using high precision fractionated stereotactic radiotherapy (FSRT) in patients with recurrent gliomas.
    Combs SE; Bischof M; Welzel T; Hof H; Oertel S; Debus J; Schulz-Ertner D
    J Neurooncol; 2008 Sep; 89(2):205-10. PubMed ID: 18461281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial.
    Combs SE; Habermehl D; Kieser M; Dreher C; Werner J; Haselmann R; Jäkel O; Jäger D; Büchler MW; Debus J
    BMC Cancer; 2013 Sep; 13():419. PubMed ID: 24034562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External beam radiation dose escalation for high grade glioma.
    Khan L; Soliman H; Sahgal A; Perry J; Xu W; Tsao MN
    Cochrane Database Syst Rev; 2020 May; 5(5):CD011475. PubMed ID: 32437039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
    Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
    J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation.
    Combs SE; Ahmadi R; Schulz-Ertner D; Thilmann C; Debus J
    J Neurooncol; 2005 Feb; 71(3):319-23. PubMed ID: 15735924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of hypofractionated proton versus carbon ion radiation therapy in patients with sacrococcygeal chordoma-the ISAC trial protocol.
    Uhl M; Edler L; Jensen AD; Habl G; Oelmann J; Röder F; Jäckel O; Debus J; Herfarth K
    Radiat Oncol; 2014 Apr; 9():100. PubMed ID: 24774721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts.
    Rieken S; Habermehl D; Haberer T; Jaekel O; Debus J; Combs SE
    Radiat Oncol; 2012 Mar; 7():41. PubMed ID: 22436135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
    Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
    J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma.
    Combs SE; Edler L; Rausch R; Welzel T; Wick W; Debus J
    Acta Oncol; 2013 Jan; 52(1):147-52. PubMed ID: 22686472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
    BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3D conformal radiotherapy and cisplatin for recurrent malignant glioma.
    VanderSpek L; Fisher B; Bauman G; Macdonald D
    Can J Neurol Sci; 2008 Mar; 35(1):57-64. PubMed ID: 18380278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of carbon ion and photon reirradiation for recurrent glioblastoma.
    Lautenschlaeger FS; Dumke R; Schymalla M; Hauswald H; Carl B; Stein M; Keber U; Jensen A; Engenhart-Cabillic R; Eberle F
    Strahlenther Onkol; 2022 May; 198(5):427-435. PubMed ID: 34523017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant irradiation of extremity soft tissue sarcoma with ions (Extrem-ion): study protocol for a randomized phase II pilot trial.
    Brügemann D; Lehner B; Kieser M; Krisam J; Hommertgen A; Jaekel C; Harrabi SB; Herfarth K; Mechtesheimer G; Sedlaczek O; Egerer G; Geisbüsch A; Uhl M; Debus J; Seidensaal K
    BMC Cancer; 2022 May; 22(1):538. PubMed ID: 35550036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.
    Blattmann C; Oertel S; Schulz-Ertner D; Rieken S; Haufe S; Ewerbeck V; Unterberg A; Karapanagiotou-Schenkel I; Combs SE; Nikoghosyan A; Bischof M; Jäkel O; Huber P; Kulozik AE; Debus J
    BMC Cancer; 2010 Mar; 10():96. PubMed ID: 20226028
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.